<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171170</url>
  </required_header>
  <id_info>
    <org_study_id>NVALT12</org_study_id>
    <nct_id>NCT01171170</nct_id>
  </id_info>
  <brief_title>Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer</brief_title>
  <acronym>NVALT12</acronym>
  <official_title>A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Society of Physicians for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dutch Society of Physicians for Pulmonology and Tuberculosis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effects of adding nitroglycerin (NTG) patches, delivery&#xD;
      25 mg NTG per 24 h, to the standard first line treatment of metastatic non-squamous non-small&#xD;
      cell lung cancer (NSCLC), i.e. 4 cycles of carboplatin-paclitaxel-bevacizumab, followed by&#xD;
      bevacizumab alone until disease progression. Tumor hypoxia is a common phenomenon in lung&#xD;
      cancer; it is a known poor prognostic marker, related to treatment resistance. Pre-clinical&#xD;
      studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia related drug&#xD;
      resistance. NTG is a NO donating drug. NTG increases tumor blood flow and thereby augments&#xD;
      antitumor drug delivery to the tumor.&#xD;
&#xD;
      A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG&#xD;
      patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with&#xD;
      advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.&#xD;
&#xD;
      The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab&#xD;
      containing chemotherapy improves progression free survival, response rate and overall&#xD;
      survival in patients with metastatic non-squamous NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for non-small cell lung cancer (NSCLC) consists of platinum-containing&#xD;
      chemotherapy. It has been shown that the addition of bevacizumab to standard chemotherapy&#xD;
      improves progression-free survival (PFS) and overall survival (OS) in patients with&#xD;
      non-squamous NSCLC. There is a need for improved PFS and OS and response rates to&#xD;
      chemotherapy are only 25-35%.&#xD;
&#xD;
      Tumor hypoxia is a common phenomenon in lung cancer; it is a known poor prognostic marker,&#xD;
      related to treatment resistance. Hypoxia Inducible Factor (HIF) -1α is the major factor&#xD;
      regulating the response to hypoxia.&#xD;
&#xD;
      HIF directly activates vascular endothelial growth factor (VEGF) and VEGF-receptor.&#xD;
      Bevacizumab interacts with this pathway by blocking VEGF.&#xD;
&#xD;
      Pre-clinical studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia&#xD;
      related drug resistance. Nitroglycerin (NTG) is a NO donating drug. NTG increases tumor blood&#xD;
      flow and thereby augments antitumor drug delivery to the tumor and inhibits HIF-1α.&#xD;
&#xD;
      Interestingly, it has recently been shown in mouse models that the addition of HIF-1α&#xD;
      inhibitors to bevacizumab significantly inhibits tumor growth by inducing apoptosis.&#xD;
&#xD;
      A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG&#xD;
      patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with&#xD;
      advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.&#xD;
&#xD;
      The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab&#xD;
      containing chemotherapy improves PFS, response rate and OS in patients with metastatic&#xD;
      non-squamous NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>every 6 weeks during chemotherapy</time_frame>
    <description>Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of the treatment</measure>
    <time_frame>every 3 weeks during chemotherapy</time_frame>
    <description>adverse events, hematology, chemistry, physial examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prediction of early response</measure>
    <time_frame>after 3 weeks</time_frame>
    <description>FDG PET scan (exploratory objective)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreased hypoxia</measure>
    <time_frame>after 6 weeks</time_frame>
    <description>FAZA scan (exploratory objective)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>carboplatin-paclitaxel-bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment plus nitroglycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin paclitaxel bevacizumab</intervention_name>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression</description>
    <arm_group_label>carboplatin-paclitaxel-bevacizumab</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment plus nitroglycerin</intervention_name>
    <description>paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle</description>
    <arm_group_label>standard treatment plus nitroglycerin</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically proven stage IV non-squamous NSCLC (according to IASLC&#xD;
             staging 7.0)&#xD;
&#xD;
          -  No prior chemotherapy or therapy with systemic anti-tumor therapy (e.g., monoclonal&#xD;
             antibody therapy) or prior exposure to agents directed at the HER axis (e.g. epidermal&#xD;
             growth factor receptor tyrosine kinase inhibitors (EGFR TKI), Herceptin). Prior&#xD;
             surgery and/or localized palliative irradiation is permitted provided that the&#xD;
             irradiated lesion is not the only measurable lesion. Prior adjuvant chemotherapy &gt; 1&#xD;
             year ago and prior treatment with an EGFR-TKI for patients with an activating EGFR&#xD;
             mutation is allowed.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG Performance Status of 0 - 2.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Subjects with at least one uni-dimensional(for RECIST) measurable lesion.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function.&#xD;
&#xD;
          -  Adequate non-hormonal contraception for females of childbearing potential during the&#xD;
             study and in the 6 months thereafter.&#xD;
&#xD;
          -  Adequate contraception for male participants (or their partners) during the study and&#xD;
             in the 6 months thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiovascular disease: congestive heart failure&#xD;
             &gt;NYHA class 2; CVA or myocardial infarction &lt; 6 months prior to study entry;&#xD;
             uncontrolled hypertension (blood pressure systolic &gt; 150 mmHg and/or diastolic &gt; 100&#xD;
             mmHg).&#xD;
&#xD;
          -  Symptomatic hypotension.&#xD;
&#xD;
          -  History of hemoptysis at least grade 2 (bright red blood of at least 2,5 ml in the&#xD;
             last 3 months)&#xD;
&#xD;
          -  Evidence of tumor invading major blood vessels on imaging (i.e. superior vena cava or&#xD;
             pulmonary artery).&#xD;
&#xD;
          -  History of HIV infection or chronic hepatitis B or C.&#xD;
&#xD;
          -  Active clinically serious infection&#xD;
&#xD;
          -  Symptomatic metastatic brain or meningeal tumors. Patients with brain metastasis may&#xD;
             be included the patient is treated with brain radiotherapy and asymptomatic.&#xD;
&#xD;
          -  History of organ allograft.&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis.&#xD;
&#xD;
          -  Non-healing wound or ulcer.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 6 months of enrolment&#xD;
&#xD;
          -  Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study&#xD;
             entry&#xD;
&#xD;
          -  Radiotherapy within 4 weeks of start of study drug. Palliative radiotherapy for bone&#xD;
             lesions is allowed &gt; 14 days of start of chemotherapy. Major surgery within 4 weeks of&#xD;
             start of study.&#xD;
&#xD;
          -  Use of vasodilators (including 5-phosphodiesterase inhibitors, calcium antagonists or&#xD;
             nitrates)&#xD;
&#xD;
          -  Autologous bone marrow transplant or stem cell rescue within 4 months of study&#xD;
&#xD;
          -  Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Marie C. Dingemans, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU medisch centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina-Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.nvalt.nl</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†. Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.</citation>
    <PMID>26347109</PMID>
  </results_reference>
  <results_reference>
    <citation>de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):8-16. Epub 2016 Sep 6.</citation>
    <PMID>27600280</PMID>
  </results_reference>
  <results_reference>
    <citation>Degens JHRJ, Sanders KJC, de Jong EEC, Groen HJM, Smit EF, Aerts JG, Schols AMWJ, Dingemans AC. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer. Lung Cancer. 2019 Jul;133:130-135. doi: 10.1016/j.lungcan.2019.05.021. Epub 2019 May 20.</citation>
    <PMID>31200819</PMID>
  </results_reference>
  <results_reference>
    <citation>de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. Clin Cancer Res. 2019 Apr 1;25(7):2219-2227. doi: 10.1158/1078-0432.CCR-18-2243. Epub 2019 Jan 14.</citation>
    <PMID>30642911</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>stage IV</keyword>
  <keyword>nitroglycerin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

